Abstract:AMP-activated protein kinase (AMPK) is an energy sensor and a key regulator of cell metabolism, hence a promising drug target. Point mutations in the regulatory γ2-subunit (encoded by PRKAG2 gene) have been shown to cause a unique form of cardiomyopathy in humans characterized by cardiac growth, arrhythmias and glycogen storage. In previous studies, we demonstrated that the mutation of prkag2 (N488I) caused aberrant activation of AMPK leading to glycogen storage. However, elimination of glycogen storage by inhibiting glycogen synthase activity failed to normalize heart weight (HW) of the mutant mice. Here, we aimed to determine whether cardiac growth in PRKAG2 ardiomyopathy was dueto cellular hypertrophy or hyperplasia. We used transgenic mice expressing a mutant PRKAG2 (N488I) in the heart (TGγ2 N488I ) that faithfully recapitulated PRKAG2 cardiomyopathy. We determined HW and cardiac myocyte size in adult (2 months) and postnatal (2 weeks) hearts in WT and TGγ2 N488I . At 2 months, TGγ2 N488I hearts show a 2.4-fold increase in HW/BW (body weight) (10.3 ± 1.44 vs. 4.3± 0.17 mg/g) as well as cross-sectional cell surface area compared WT hearts (325 ± 13 vs. 155 ± 5.4 μm 2 ,p<0.01), suggesting cellular hypertrophy in adult TGγ2 N488I heart. Furthermore, we observed increased mTOR activity evidenced by enhanced phosphorylation of mTOR (Ser2448) as well as its downstream targets S6 and 4E-BP. The HW of TGγ2 N488I was partially inhibited by treatment with rapamycin, an inhibitor of mTOR. Interestingly, the length and width of isolated cardiomyocytes from 2 weeks old mice were not different between the WT and TGγ2 N488I heart in spite of a 50% increase of HW of TGγ2 N488I mice. We observed a 2- fold increase in the expression of a proliferation marker, proliferating cell nuclear antigen (PCNA) during postnatal cardiac growth. Expression of Cyclin genes including cyclin D1, D2 and E1 was greatly increased in TGγ2 N488I hearts (2.4 - 4 fold, p<0.01 vs. WT). Taken together, these data indicate that aberrant γ2-AMPK activation stimulates cardiac growth through increased cell number during postnatal growth period and increased cell size at adulthood. These results suggest a novel role of γ2-AMPK in the growth of cardiac myocytes.

AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation

O-GlcNAcylation Involvement in High Glucose-Induced Cardiac Hypertrophy Via ERK1/2 and Cyclin D2

Activation of AMPK Inhibits Cardiomyocyte Hypertrophy by Modulating of the FOXO1/MuRF1 Signaling Pathway in Vitro

AMPK Attenuates Microtubule Proliferation in Cardiac Hypertrophy.

GW24-e2121 Adenosine Monophosphate-Activated Protein Kinase Attenuates Cardiomyocyte Hypertrophy Through Regulation of FOXO3a/MAFbx Signalling Pathway

Abstract 17221: AMPK Regulation of Microtubule Dynamics in Cardiac Hypertrophy

Abstract 15090: AMP-Activated Protein Kinase Upregulates Sodium-Dependent Glucose Transporter SGLT1, Which Contributes to Cardiac Ischemia-Reperfusion Injury

Long-Term Activation of Adenosine Monophosphate-Activated Protein Kinase Attenuates Pressure-Overload-Induced Cardiac Hypertrophy

The role of AMP-activated protein kinase in the cardiovascular system

AMPK activation attenuates S6K1, 4E-BP1, and eEF2 signaling responses to high-frequency electrically stimulated skeletal muscle contractions

Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction

AMPK blunts chronic heart failure by inhibiting autophagy.

Limiting Cardiac Ischemic Injury by Pharmacological Augmentation of Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Signal Transduction

Regulation of the Proteasome by AMPK in Endothelial Cells: the Role of O-GlcNAc Transferase (OGT)

Amp Activated Protein Kinase-Alpha 2 Deficiency Exacerbates Pressure-Overload-Induced Left Ventricular Hypertrophy and Dysfunction in Mice

AMP-activated Protein Kinase Modulates Cardiac Autophagy in Diabetic Cardiomyopathy

Regulation of miR-199a expression by AMPK in cardiac tissues

AMPK is indispensable for overload‐induced muscle glucose uptake and glycogenesis but dispensable for inducing hypertrophy in mice

AMPK and O-GlcNAcylation: interplay in cardiac pathologies and heart failure

Targeting the energy guardian AMPK: another avenue for treating cardiomyopathy?

Abstract 73: Aberrant Activation of γ2-AMPK Increases Cardiac Growth Through Cellular Hypertrophy and Hyperplasia